Get the Stockscreener App
35.55
2.34%
-0.85
After Hours:
36.00
0.45
+1.27%
Alto Neuroscience Inc stock is traded at $35.55, with a volume of 269.72K.
It is down -2.34% in the last 24 hours and up +25.93% over the past month.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
See More
Previous Close:
$36.40
Open:
$36.175
24h Volume:
269.72K
Relative Volume:
0.53
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
$-74.31M
P/E Ratio:
-14.32
EPS:
-2.4817
Net Cash Flow:
$-62.86M
1W Performance:
+1.20%
1M Performance:
+25.93%
6M Performance:
+65.89%
1Y Performance:
+912.82%
1-Day Range:
$35.45
$36.98
1-Week Range:
$33.98
$37.39
52-Week Range:
$3.47
$37.48
Alto Neuroscience Inc Stock (ANRO) Company Profile
Name
Alto Neuroscience Inc
Sector
Industry
Phone
773-255-5012
Address
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
35.55 | 1.34B | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Nov-17-25 | Initiated | BTIG Research | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Oct-23-24 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| Oct-23-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-03-24 | Initiated | Wedbush | Outperform |
| Feb-27-24 | Initiated | Jefferies | Buy |
| Feb-27-24 | Initiated | Robert W. Baird | Outperform |
| Feb-27-24 | Initiated | Stifel | Buy |
| Feb-27-24 | Initiated | TD Cowen | Outperform |
| Feb-27-24 | Initiated | William Blair | Outperform |
View All
Alto Neuroscience Inc Stock (ANRO) Latest News
HC Wainwright Issues Optimistic Forecast for ANRO Earnings - MarketBeat
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com
H.C. Wainwright raises Alto Neuroscience price target to $55 By Investing.com - Investing.com Canada
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High on Analyst Upgrade - MarketBeat
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
HC Wainwright Increases Alto Neuroscience (NYSE:ANRO) Price Target to $55.00 - MarketBeat
Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding? - Sahm
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Yahoo Finance
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline? - Yahoo Finance
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Yahoo Finance
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - Sahm
Alto Neuroscience (ANRO) Slips 0.5% as Stock Holds Above Key $30.53 SupportFund Manager Survey - vinanet.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap - Stock Titan
Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A - Stock Titan
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating - Moomoo
Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7%Here's Why - MarketBeat
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.56, Implies 16% Upside - TradingView
Sirenia Capital (ANRO) discloses 2.22M Alto Neuroscience shares under beneficial ownership - Stock Titan
BofA Adjusts Price Target on Alto Neuroscience to $37 From $33 - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT) - The Globe and Mail
Alto Neuroscience stock hits all-time high at 32.74 USD By Investing.com - Investing.com Canada
Alto Neuroscience stock hits all-time high at 32.74 USD - Investing.com
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Alto Neuroscience (NYSE:ANRO) Trading 8% Higher Following Earnings Beat - MarketBeat
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $37.11, Implies 27% Upside - TradingView
Wedbush Forecasts Strong Price Appreciation for Alto Neuroscience (NYSE:ANRO) Stock - MarketBeat
Alto Neuroscience (NYSE:ANRO) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $36.89, Implies 26% Upside - TradingView
ALTO NEUROSCIENCE INC : BTIG RAISES TARGET PRICE TO $37 FROM $28 - Bitget
Alto Neuroscience Q2 EPS beats estimates; completes $100M financing - scanx.trade
Alto Neuroscience (NYSE:ANRO) Announces Quarterly Earnings Results - MarketBeat
Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges - stocktitan.net
Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands - Quiver Quantitative
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
Alto Neuroscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week HighShould You Buy? - MarketBeat
Alto Neuroscience Escapes Investor Drug Trial Suit, For Now - Law360
Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Shareholders SueWallSt in New Class Action Against Alto Neuroscience, Inc.Act Now - The National Law Review
Alto Neuroscience stock hits all-time high at 29.34 USD By Investing.com - Investing.com Australia
Alto Neuroscience (NYSE:ANRO) Sets New 12-Month HighShould You Buy? - MarketBeat
Alto Neuroscience stock hits all-time high at 29.34 USD - Investing.com
Alto Neuroscience (ANRO) Projected to Announce Earnings on Wednesday - MarketBeat
Alto Neuroscience (ANRO) Slips 0.71% as Shares Test Key Support ZoneUpthrust Pattern - Vinanet
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Alto Neuroscience, Inc. (ANRO) - The National Law Review
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO) - Seeking Alpha
Alto Neuroscience Inc Stock (ANRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):